Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Eukaryotic translation initiation factor 4A1 pseudogene 12 (EIF4A1P12) is a processed pseudogene of the EIF4A1 gene. Pseudogenes possess DNA sequence similarity to known genes but are generally considered nonfunctional—they typically lack the ability to encode a protein due to disabling mutations such as frameshifts or premature stop codons. EIF4A1P12 is listed among numerous processed pseudogenes related to elongation factors in humans and is not reported to have any protein-coding or targetable function[6][1][5]. EIF4A1P12 is a non-functional, processed pseudogene with no evidence as a drug or therapeutic target. It should not be considered a valid target for pharmacological intervention.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Eukaryotic translation initiation factor 4A1 pseudogene 12 (EIF4A1P12).